Suchergebnisse - "Orlando, Laura"

PubPharm (6)

1

Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer : Final Results From the Phase 2 METEORA-II Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Munzone, E. | Regan, M. | Cinieri, S. | +60

2

Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer : A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Orlando, L. | Lorusso, V. | Giotta, F. | +15

3

A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer : Could be an old regimen a valid approach to a changing disease?

enthalten in: The breast journal | 2020

von Ciccarese, M. | Orlando, L. | Fedele, P. | +19

4

EFFECT : a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

enthalten in: Breast cancer research : BCR | 2020

von Biganzoli, L. | Cinieri, S. | Berardi, R. | +23

5

Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer : results of a Phase II GOIM study

enthalten in: Future oncology (London, England) | 2014

von Orlando, L. | Giotta, F. | Lorusso, V. | +13

6

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer : results of the randomized phase II CHER-LOB study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012

von Guarneri, V. | Frassoldati, A. | Bottini, A. | +18

CommentIn: J Clin Oncol. 2012 Jun 1;30(16):1909-11. - PMID 22493414

1
[1]